Amanote Research
Register
Sign In
P3.13-34 RET Gene, a New Choice for NSCLC
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1875
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
Y. Wang
K. Ma
Y. Xu
Publisher
Elsevier BV
Related search
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A New Polymorphism in Theretprotooncogene (RET)
Nucleic Acids Research
Genetics
P3.13-28 Heterogeneity, Prevalence and Prognostic Significance of PDL1 Expression in Early Resected NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-01 Detecting ALK Rearrangements in NSCLC Patients: IHC, FISH or NGS Fusion?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-33 Lung Adenocarcinoma Harboring RET Fusion and Dramatic Response to Combination of Vandetanib (VAN) and Everolimus (EVE): A Case Report From Brazil
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-31 Creating a Precision Medicine Pipeline for Lung Cancers.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary